MDC Webinar: Rapid Research Rounds | Muscular Dystrophy Canada 2020 Neuromuscular Conference
Rapid Research Rounds
This session is an introduction to the 12 latest MDC funded research awardees. The projects span from early discovery, translational and clinical research as well as address critical gaps in Canada’s ecosystem. All of these projects were selected through competitive medical and scientific peer review process and have recently started. You will hear introductions to these projects, get to know the people behind the research and hear about the impact that donations raised by our neuromuscular community have on research.
For a full list of past MDC funded research please see: https://muscle.ca/access-help/research/projects-currently-funded/
NMD4C Members Involvement
We are excited to have strong representation from NMD4C members amongst those presenting, and encourage you to take this opportunity to learn about some of the work being done by our members!
For more information please visit the event page.
Register Now!
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.